Tillkännagivande • Apr 29

Biomea Fusion, Inc. Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion, Inc. had announced positive 52-week results from its Phase 2 COVALENT-112 trial evaluating the efficacy, safety, and tolerability of icovamenib in patients with type 1 diabetes (“T1D”). These data are based on a proof-of-concept study enrolling small subsets of Stage 3 T1D patients dosed with icovamenib at 100 mg and 200 mg in two cohorts (patients diagnosed within 3 years and those diagnosed within 3-15 years). The COVALENT-112 trial demonstrated encouraging results in patients with T1D. In patients diagnosed within 0-3 years, treatment with icovamenib 200 mg once daily for 12 weeks resulted in a 52% increase in mean C-peptide area under the curve (AUC) at Week 12 (p < 0.001; n=5), representing a magnitude of improvement that is not commonly reported in published studies of T1D. The effect was durable following only 12 weeks of dosing, mean C-peptide AUC was largely preserved through Week 52, representing approximately a 7% decline from baseline. A dose response was observed, with the 200 mg dose demonstrating greater activity compared to 100 mg. Published natural history data suggest that patients with Stage 3 T1D typically experience substantial declines in C-peptide over time, underscoring the significance of preserved C-peptide following only a 12-week dosing period. In patients with longer-standing disease (3-15 years since diagnosis), C-peptide levels were generally preserved through Week 52 (12-week treatment period + 40-week follow-up), with only a modest decline from baseline. Icovamenib was generally well tolerated, with no new or unexpected safety signals identified throughout the 52-week observation period. Unlike investigational approaches in T1D that rely primarily on immune suppression or cellular transplantation, icovamenib is designed as a short course, orally administered therapy targeting beta cell biology, with effects that appear to persist beyond the treatment period. Based on these data, Biomea, in collaboration with four U.S. academic centers, is planning a Phase 2 trial in patients with T1D diagnosed within the past 3 years. The study will evaluate whether extended dosing (up to 6 or 12 months) at 200 mg further improves C-peptide and whether the addition of an immunosuppressive agent enhances clinical outcomes. This study is planned to be initiated within the second half of this year at the Barbara Davis Center for Diabetes, Joslin Diabetes Center, UT Health San Antonio Diabetes Center, and the University of Miami Diabetes Research Institute. COVALENT-112 (NCT06152042) was an open label Phase 2 trial evaluating icovamenib in adult patients with T1D. The study enrolled patients aged 18 to 60 years with Stage 3 T1D, including those diagnosed within 0–3 years with residual beta cell function at baseline, defined by a screening C-peptide level =0.2 nmol/L (Cohort 1), as well as a broader population with disease duration of 3–15 years and residual beta cell function at baseline, defined by a screening C-peptide level =0.08 nmol/L (Cohort 2). Participants were assigned to receive icovamenib at 100 mg or 200 mg once daily for 12 weeks, followed by a 40-week post-treatment follow-up to assess durability of effect. Study enrollment and dosing were interrupted in May 2024 due to an FDA clinical hold, which was subsequently resolved. As a result, these data reflect approximately half of the originally intended patient population. A planned placebo-controlled Part 2 of the study was not completed. The primary endpoint was the mean change from baseline in stimulated C-peptide area under the curve (AUC), measured during a mixed-meal tolerance test (MMTT), to evaluate endogenous insulin secretion. Secondary endpoints included additional measures of beta cell function, glycemic control, insulin use, and safety. Icovamenib is an orally administered investigational small molecule currently in Phase 2 clinical development for the treatment of diabetes. Icovamenib targets menin, a transcriptional regulator implicated in beta cell dysfunction, and has been shown in preclinical and clinical studies to induce transient reductions in menin protein levels in pancreatic islets, thereby modulating pathways associated with insulin secretion and glycemic control. Through this mechanism, icovamenib has the potential to restore beta cell mass and function and improve endogenous insulin production. As a potential short-course therapy, icovamenib could represent a novel treatment approach for patients with diabetes, particularly those who have not achieved adequate control with standard-of-care therapies. Loss of functional beta cell mass is a core component of the natural history in both major types of diabetes, T1D (mediated by autoimmune dysfunction) and T2D (mediated by metabolic dysfunction). Beta cells are found in the pancreas and are responsible for the synthesis and secretion of insulin. Insulin is a hormone that helps the body use glucose for energy and helps control blood glucose levels. In patients with diabetes, beta cell mass and function have been observed to be diminished, leading to insufficient insulin secretion and hyperglycemia. Menin is thought to act as a brake on beta cell turnover and growth, supporting the hypothesis that inhibition of menin may enable pathways associated with beta cell regeneration and improved function. Based on these and other scientific findings, Biomea is exploring the potential for icovamenib-mediated menin inhibition as a viable therapeutic approach to treat T1D and T2D. Type 1 diabetes (T1D) is a chronic autoimmune disease in which the body’s immune system destroys insulin-producing beta cells in the pancreas, leading to a loss of endogenous insulin production. Approximately 9,500,000 people worldwide live with T1D, with an estimated 513,000 new diagnoses each year. In the United States, about 1,800,000 individuals are affected. At diagnosis, patients often have already lost a significant portion of their functional beta cell mass, and this decline typically continues over time. As a result, individuals with T1D require lifelong insulin therapy and continuous glucose monitoring to manage blood sugar levels. Despite advances in care, T1D remains associated with meaningful risks, including severe hypoglycemia and diabetic ketoacidosis (DKA), as well as long-term complications such as cardiovascular disease, kidney disease, nerve damage, and vision loss. There are currently no approved therapies that address the underlying progressive loss of beta cell function in established (Stage 3) T1D beyond insulin replacement, highlighting a significant unmet medical need for disease-modifying treatments.

Räntetäckningsgrad	n/a
Kontanter	US$44.69m
Eget kapital	US$18.72m
Summa skulder	US$27.67m
Totala tillgångar	US$46.39m

Uppgifter	Senast uppdaterad (UTC-tid)
Analys av företag	2026/06/14 14:59
Aktiekurs vid dagens slut	2026/06/12 00:00
Intäkter	2026/03/31
Årlig intjäning	2025/12/31

Paket	Uppgifter	Tidsram	Exempel US-källa
Företagets finansiella ställning	10 år	Resultaträkning Kassaflödesanalys Balansräkning	SEC Form 10-K SEC Form 10-Q
Analytikernas konsensusuppskattningar	+3 år	Prognos för finansiella poster Analytikernas prismål	Rapporter från analytiker Blue Matrix
Marknadspriser	30 år	Aktiekurser Utdelningar, splittar och åtgärder	ICE Marknadsdata SEC Form S-1
Ägarskap	10 år	Största aktieägare Insiderhandel	SEC Formulär 4 SEC Formulär 13D
Förvaltning	10 år	Ledningsgrupp Styrelse och verkställande direktörer	SEC Form 10-K SEC Form DEF 14A
Viktiga utvecklingstendenser	10 år	Företagsmeddelanden	SEC Formulär 8-K

Analytiker	Institution
Naureen Quibria	Capital One Securities, Inc.
Yigal Nochomovitz	Citigroup Inc
Jonathan Wolleben	Citizens JMP Securities, LLC

Biomea Fusion Balansräkning Hälsa

Finansiell hälsa kriterier kontrolleras 4/6

Viktig information

Nya uppdateringar om finansiell hälsa

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

Recent updates

Price target decreased by 9.7% to US$6.83

New minor risk - Market cap size

Biomea Fusion, Inc. Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment

Biomea Fusion, Inc., Annual General Meeting, Jun 10, 2026

Biomea Fusion, Inc. Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies

New major risk - Financial position

Biomea Fusion Presents Phase II Covalent-111 Data In Type 2 Diabetes At 19th International Conference On Advanced Technologies And Treatments For Diabetes

Biomea Fusion, Inc. Presents Covid-111 Study Results At the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

Co-Founder recently bought US$55k worth of stock

Biomea Fusion, Inc. Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide At Obesityweek®? 2025

Price target decreased by 10% to US$7.17

Biomea Fusion, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2025

Biomea Fusion, Inc. Announces First Patient Dosed in Phase I Study of BMF-650 A Next-Generation Oral GLP-1 Receptor Agonist

Biomea Fusion Announces Positive 52-Week Results from Phase II Covid-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines

Biomea Fusion, Inc. has filed a Follow-on Equity Offering.

Biomea Fusion, Inc. Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

Price target decreased by 27% to US$8.29

Biomea Fusion, Inc. Announces Board Changes

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Index

Biomea Fusion, Inc. Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

New major risk - Shareholder dilution

Biomea Fusion, Inc. has filed a Follow-on Equity Offering.

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent Flt3 Inhibitor Bf-500 in Relapsed or Refractory Acute Leukemia At Eha 2025

New major risk - Share price stability

Price target decreased by 14% to US$20.00

Biomea Fusion, Inc. Selects for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Price target decreased by 13% to US$20.50

Biomea Fusion, Inc., Annual General Meeting, Jun 11, 2025

Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt

Biomea Fusion, Inc. Announces Chief Executive Officer Changes

Biomea Fusion Inc. Announces Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-Cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Price target decreased by 34% to US$28.11

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion, Inc. Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

High number of new and inexperienced directors

Independent Director recently bought US$101k worth of stock

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc. Announces FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

New major risk - Financial position

High number of new and inexperienced directors

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023